Dawson James Small Cap Growth Conference

October 15, 2015

Wyndham Grand Jupiter - Jupiter, Florida

 

Dawson James is a full day, two-track investor conference featuring more than 30 companies spanning healthcare/technology and consumer sectors, as well as an "Uplist Boot Camp." Taking place at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida, the Dawson James conference will host an attendance of institutional, family office and high-net worth clients.

8:30 am

AxoGen, Inc. (AXGN)

AxoGen, Inc. (NASDAQ: AXGN) is a medical technology company dedicated to peripheral nerve repair. The company's portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard® Nerve Connector, for tensionless repair of severed nerves; and AxoGuard® Nerve Protector, a product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. For more information, visit the company's website at www.axogeninc.com.

Pulmatrix, Inc. (PULM)

Pulmatrix, Inc. (NASDAQ: PULM) is developing innovative inhaled therapies to address serious pulmonary disease using its clinically validated, proprietary iSPERSE technology. Leveraging the unique capabilities of iSPERSE to dramatically advance inhalation technology, the company means to create new therapies to improve patient outcomes. Pulmatrix's pipeline of inhaled therapies represents innovative, first-in-class products. This proprietary pipeline of novel, therapies for rare, orphan diseases is led by PUR1900, an inhaled anti-infective to treat fungal infections in cystic fibrosis or immune compromised patients. For more information, visit the company's website at www.pulmatrix.com.

9:00 am

Cel-Sci Corp. (CVM)

Cel-Sci Corp. (NYSE: CVM) aims to find the best way to activate the immune system to fight cancer and infectious diseases. The company's lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is currently being studied in a pivotal phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the head and neck. Additional clinical indications for Multikine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. For more information, visit the company's website at www.cel-sci.com.

InspireMD, Inc. (NSPR)

InspireMD, Inc. (NYSE: NSPR) was founded in 2005 with the purpose of creating a technology that could solve the problem of embolization in high risk vascular procedures. The company has grown to include a portfolio of embolic protection systems, which it both manufactures and commercializes. Today, InspireMD is a global company headquartered in Boston, Massachusetts, seeking to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection by providing a superior solution to the key clinical issues of vascular procedures. For more information, visit the company's website at www.inspire-md.com.

9:30 am

Nephros, Inc. (NEPH)

Nephros, Inc. (OTCBB: NEPH), a commercial stage medical device company, develops and sells high-performance liquid purification ultra-filters and an online mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease. Its ultra-filters are primarily used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and/or blood. Nephros was founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize a hemodiafiltration system, an alternative method to hemodialysis. For more information, visit the company's website at www.nephros.com.

TapImmune Inc. (TPIV)

TapImmune Inc. (OTCQB: TPIV) is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases. The company's peptide or nucleic acid-based immunotherapeutics comprise one or more naturally processed epitopes designed to comprehensively stimulate patients' T-cells while restoring or further augmenting antigen presentation. TapImmune's technologies are suitable for use as stand-alone medications, as well as in combination with current treatment modalities. For more information, visit the company's website at www.tapimmune.com.

10:15 am

Finjan Holdings, Inc. (FNJN)

Finjan Holdings, Inc. (NASDAQ: FNJN) offers investors a diversified and unique vehicle for investing in cybersecurity-related intellectual property-backed technologies under the guidance of a proven team. Finjan's commitment to innovation in the security space continues through its investments which have culminated in the recent launch of Finjan's consulting services business, CybeRisk, development of mobile applications for the consumer and incubation of up-and-coming technology startups pioneering a new generation of security technologies. For more information, visit the company's website at www.finjan.com.

Check-Cap Ltd. (CHEK)

Check-Cap Ltd. (NASDAQ: CHEK) is a clinical stage medical diagnostics company leading the development of the first ingestible imaging capsule that utilizes low-dose X-rays for CRC screening. The Check-Cap device requires no bowel preparation or invasive procedures, and is designed to detect clinically significant polyps with a high degree of sensitivity. Check-Cap's advanced technology has been proven in animals, and is designed to offer several advantages compared to current screening procedures. For more information, visit the company's website at www.check-cap.com.

10:45 am

RestorGenex Corporation (RESX)

RestorGenex Corporation (OTCQB: RESX) is a specialty biopharmaceutical company focused on the development of a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space. The company's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. RestorGenex's current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. For more information, visit the company's website at www.restorgenex.com.

Galmed Pharmaceuticals Ltd. (GLMD)

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, Aramchol™, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.For more information, visit the company's website at www.galmedpharma.com.

11:15 am

Oculus Innovative Sciences, Inc. (OCLS)

Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) has designed a humanitarian program to respond to unexpected disasters—floods, earthquakes, tsunamis, hurricanes, epidemics and even man-made calamities—by providing product (such as food or medical assistance) to these victims. The product will be available according to the regulatory claims in each area and at the request of emergency first responders and foundations. To this end, Oculus is proactively seeking partnerships with international aid groups that respond to relief needs and improve global health care services. For more information, visit the company's website at www.oculusis.com.

11:45 am

Aeterna Zentaris, Inc. (AEZS)

Aeterna Zentaris, Inc. (NASDAQ: AEZS) is a specialty biopharmaceutical company engaged in the development and commercialization of novel treatments in the fields of oncology, endocrinology and women's health. The company's product pipeline includes Macrilen™, which is currently in phase III clinical testing for the diagnosis of adult growth hormone deficiency, as well as zoptarelin doxorubicin, which is in phase III clinical development for the treatment of endometrial cancer. For more information, visit the company's website at www.aezsinc.com.

Capnia, Inc. (CAPN)

Capnia, Inc. (NASDAQ: CAPN) Capnia, Inc. (NASDAQ: CAPN) develops diagnostic and therapeutic products based on its proprietary technology for the precision metering of gas flow. Operating primarily in the U.S., the company offers CoSense for the diagnosis of excessive hemolysis in neonates, a condition that causes long-term developmental disability due to the degradation of red blood cells. It also develops Serenz, a therapeutic product candidate that has completed phase II clinical trials for the treatment of symptoms related to allergic rhinitis. For more information, visit the company's website at www.capnia.com.

12:45 pm

Atossa Genetics Inc. (ATOS)

Atossa Genetics Inc. (NASDAQ: ATOS) is focused on improving breast health through the development of innovative laboratory services, medical devices and therapeutics. The company's laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. These services, as well as Atossa's medical devices, are being developed so they can be used as companions to therapeutics aimed at the treatment of various breast health conditions. For more information, visit the company's website at www.atossagenetics.com.

VolitionRx (VNRX)

Life sciences company VolitionRx (NYSE: VNRX) is developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. The company's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's R&D activities are centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide. For more information, visit the company's website at www.volitionrx.com.

1:15 pm

BioLife Solutions, Inc. (BLFS)

BioLife Solutions, Inc. (NASDAQ: BLFS) is located in Bothell, Washington, on a high-tech campus that has roots as a dairy farm. The company manufactures and markets proprietary protein-free, serum-free cGMP biopreservation media for cells, tissues and organs. BioLife Solutions performs contract R&D and offers consulting to optimize customer-specific biopreservation protocols and processes. And for its direct, distributor and contract customers, it provides custom formulation, fill and finish services. For more information, visit the company's website at www.biolifesolutions.com.

Great Basin Scientific, Inc. (GBSN)

Founded in 2005, Great Basin Scientific, Inc. (NASDAQ: GBSN) is a molecular diagnostics company commercializing breakthrough technologies that improve ease-of-use and deliver better cost per result for sample-to-result molecular diagnostic testing. The company's breakthrough molecular diagnostic system provides more diagnostics data per test, and its ease of use and lower price is designed to help reduce costs for the entire healthcare industry. For more information, visit the company's website at www.gbscience.com.

1:45 pm

Latitude 360, Inc. (LATX)

Latitude 360, Inc. (OTC: LATX) is an award-winning pioneer of combining premier upscale casual dining with state-of-the-art entertainment creating a "360 Experience" in its unique venues. The Company develops, constructs and operates cutting-edge Latitude 360 locations (from 50,000-70,000 sq. ft.) that appeal to a broad base of consumers and corporate clients. Current locations can be found in Jacksonville, Pittsburgh, and Indianapolis. Management plans to open three new venues per year for the next four years. Two new locations in Syracuse, NY and Bethlehem, PA are expected to operate as Latitude 360 locations in the fourth quarter of this year. For more information, visit the company's website at www.latitude30.com.

3:00 pm

Payment Data Systems, Inc. (PYDS)

Payment Data Systems, Inc. (NASDAQ: PYDS) is an integrated payment solutions provider to merchants and billers. The company provides an extensive set of products to deliver world-class payment acceptance. Payment Data has solutions for merchants, billers, banks, service bureaus and card issuers. The strength of the company is its ability to offer specifically tailored solutions for card issuance, payment acceptance and bill payments. For more information, visit the company's website at www.paymentdata.com.

3:30 pm

Nemus Bioscience, Inc. (NMUS)

Nemus Bioscience, Inc. (OTC: NMUS) Nemus Bioscience, Inc. (OTC: NMUS) is a biopharmaceutical company with a focus on the discovery, development and commercialization of therapeutics based on naturally-derived or synthetically manufactured cannabis compounds. The company develops therapeutic products to treat glaucoma and other optic nerve-related disorders and conditions associated with muscle spasticity, epilepsy, anxiety, and methicillin-resistant staphylococcus aureus. Founded in 2012, the company is based in Costa Mesa, California. For more information, visit the company's website at www.nemusbioscience.com.

4:00 pm

RXi Pharmaceuticals Corp. (RXII)

RXi Pharmaceuticals Corp. (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics that address high-unmet medical needs, primarily in the area of dermatology and ophthalmology. Its discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents, and includes its proprietary, self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring. It also includes an immunomodulator, Samcyprone, a proprietary topical formulation of diphenylcyclopropenone (DPCP) for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma. For more information, visit the company's website at www.rxipharma.com.